| #1 | | | Istanbul, Turkey | | 22+ years | Immunotherapy with Keytruda | Advanced or metastatic cancers | Uses Keytruda (pembrolizumab) for targeted immunotherapy. Partnered with Johns Hopkins Hospital, JCI accredited, and offers comprehensive oncology services with advanced diagnostic tools. | International Organization for Standardization, Joint Commission International |
| #2 | | | Istanbul, Turkey | | 29+ years | Immunotherapy with Keytruda (Pembrolizumab), combination therapy with chemotherapy | Lung cancer and gastrointestinal cancers | JCI-accredited hospital with specialized oncologists. Offers Keytruda immunotherapy combined with chemotherapy, administered every three weeks. Doctors have led clinical trials in targeted therapies. | Joint Commission International , International Organization for Standardization |
| #3 | | | Istanbul, Turkey | | 23+ years | Immunotherapy with Keytruda (Pembrolizumab), Immunotherapy combined with chemotherapy, Monoclonal Antibody Triple Therapy | Lung, esophageal, and gastric cancers | Specializes in personalized immunotherapy with Keytruda, offers combined therapy approaches, and has a 98% patient recommendation rate. Doctors have performed 1,100+ procedures. | Turkish Medical Association, International Health Tourism Authorization Certificate |
| #4 | | | Milan, Italy | | 57+ years8,000+ treatments | Immunotherapy with Keytruda (Pembrolizumab) | Lung cancer treatment | Specializes in oncology with a multidisciplinary team. Clinic performs 52,000 operations annually and offers tailored immunotherapy programs. 4.5-star rating based on patient reviews. | Scientific Institute for Research and Healthcare Accrediatation, World's Best Hospitals 2021 by Newsweek |
| #5 | | | Barcelona, Spain | | 41+ years23,000+ treatments | Immunotherapy with Keytruda (Pembrolizumab) | Advanced or metastatic cancers | Offers immunotherapy with Keytruda, follows Memorial Sloan-Kettering protocols, and has a multidisciplinary team for personalized cancer treatment plans. | Joint Commission International , European Foundation for Quality Management |
| #6 | | | Istanbul, Turkey | | 14+ years | Immunotherapy with Keytruda (Pembrolizumab), combined two-drug immunotherapy | Metastatic melanoma and renal cancer | JCI-accredited clinic with a 90% organ transplant success rate. Specializes in oncology and offers personalized treatment plans under experienced oncologists. | International Organization for Standardization, Joint Commission International |
| #7 | | | Tel Aviv, Israel | | 39+ years34,000+ treatments | Immunotherapy with Keytruda (Pembolizumab) | Advanced or metastatic cancer cases | Sourasky Medical Center has a 90% success rate in oncology treatments, offers personalized immunotherapy, and is JCI accredited with a multidisciplinary approach. | World's Best Smart Hospitals 2021 by Newsweek, World's Best Hospitals 2021 by Newsweek |
| #8 | | | Istanbul, Turkey | | 20+ years | Immunotherapy with Keytruda (Pembrolizumab), MSI testing | Metastatic colorectal cancer | JCI-accredited oncology center with personalized immunotherapy programs. Offers MSI testing to determine Keytruda suitability, ensuring targeted treatment. Doctors have managed complex cancer cases with international training. | Joint Commission International , Turkish Medical Association (Türk Tabıplerı Bırliği) |
| #9 | | | Istanbul, Turkey | | 24+ years | Immunotherapy with Keytruda (Pembolizumab) | Metastatic melanoma or breast cancer | Offers immunotherapy with Keytruda, a leading treatment for advanced cancers, with personalized care plans and international patient support. 91% of clients recommend the clinic. | International Organization for Standardization, Joint Commission International |
| #10 | | | Antalya , Turkey | | 16+ years | PET/CT, Angiography | — | — | Joint Commission International |